1st #ATTC deal for @hutchmed with @GSK for $110m upfront & up to $1 .25bn in milestones provides clear external validation of the ATTC platform’s clinical & commercial attractions, & accelerates the global development of KRAS/EGFR programme HMPL-A830 #HCM

Positive SAFFRON topline PFS/OS data suggest well-tolerated all-oral #savolitinib/#Tagrisso combo cld offer a differentiated treatment option in 2L EGFRm MET-amp #NSCLC. Ex-China reg approval(s) from 2027/8 wld make savo @hutchmed's 2nd global product $HCM

Strategic RTO of $NEUP to unlock long-term value, providing @scancellpharma w a NASDAQ listing & funding for the pivotal iSCIB1+ #melanoma study. ~$89m of new equity from UK & US investors & Blackrock debt will extend $SCLP cash into 2029

FAP-Dox (Gen 1) data supports the pre|CISION concept, but @avacta's Gen 2 (sustained release) & 3 (dual payload) progs could address a broader range of solid tumours w potential for improved or at least equivalent payload delivery to marketed ADCs #AVCT

Lead #ImmunoBody asset iSCIB1+ showed durable responses in the Ph 2 SCOPE trial; more mature data expected early-2027. FDA agreement on trial design means @scancellpharma could start Ph 3 in 2026, subject to funding. #SCLP $SCLP

China rev growth for @hutchmed will be driven by new products & indications. #Savolitinib on track to become 2nd global asset; H226 SAFFRON data. ATTCs (2 in Ph I) combine targeting mAb & small molecule targeted payload & cld provide partner opps #HCM $HCM

£9m raise at mkt price to settle 3 CB repayments suggests solid confidence in the future potential of the #preCISION platform & @avacta's ability to deliver. For more on #AVCT $AVCT

H126 @avacta catalysts include #AVA6000 SGC data at #ASCO2026, #BIO presentation; w 1st #AVA6103 Ph Ia data & #AVA6207 payload disclosure/candidate selection in H226. +ve news cld extend Q127 cash runway via potential partnering, investment, or both #AVCT

Successful £10m raise extends runway into Q127, removes funding uncertainty & allows @avacta to retain 100% ownership of #preCISION tech & assets through key data catalysts for FAP-Dox & FAP-Exd. For more on #AVCT:

Innovative synthetic AI analysis by @avacta shows 3 key benefits of #AVA6103 (pre|CISION #exatecan PDC) vs #Enhertu (marketed #deruxtecan ADC): more rapid drug penetration into tumour; >10x more drug in the tumour; c3x higher tumour selectivity. #AVCT

FDA IND for Ph III iSCIB1+ #melanoma study is a major milestone for @scancellpharma, clearing the pathway for its further development. The focus is now on evaluating financing options for the trial; partnering is one option. For more on #SCLP $SCLP see:

Growing preclinical & clinical data support potential utility & value of @avacta's preCISION platform. Pipeline progressing w/ AVA6103 Ph I start in Q126 (initial data H226), AVA6000 Ph I TNBC data in H1 & AVA6207 candidate selection by yr end #AVCT $AVCT